MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$2,033K
Free Cash flow
-$3,291K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Proceeds from issuance of pre-fu...
Accounts payable and accrued exp...
Others
Negative Cash Flow Breakdown
Net loss
Research and development supplie...
Repayments of short-term borrowi...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-4,117
-5,000
-3,244
-15,402
Change in fair value of warrant liability
-
-
0
0
Change in fair value of forward contract liability
-
-
0
0
Commitment fee payable
-
-
-
0
Payable to parent
-
-
0
0
Change in fair value of sepa put option liability
0
54
329
23
Change in fair value of convertible debt
0
0
-810
-846
Commitment fee expense
-
-
0
-
Gain on termination of warrant and commitment fee liabilities
-
-
0
-
Non-cash original discount on convertible debt
0
-
0
625
Stock-based compensation expense
707
694
702
704
Gain on termination of operating lease
32
-
-
-
Amortization of operating lease right-of-use asset
95
171
168
166
Depreciation expense
66
66
66
65
Research and development supplies and other current assets
1,807
-
-
-
Prepaid expenses
-492
-435
1,082
-960
Accounts payable and accrued expenses
971
-95
-124
-732
Other current assets
-403
403
0
0
Other assets
0
-
0
0
Operating lease liability
-69
-178
-130
-170
Net cash used in operating activities
-3,291
-4,364
-3,163
-3,972
Purchases of property and equipment
0
0
0
6
Net cash used in investing activities
0
0
0
-6
Proceeds from short-term convertible debt
327
-
4,375
-
Proceeds from short-term borrowing
-
-
-4,375
0
Repayments of short-term borrowing
203
-
0
0
Proceeds from loan payable
-
327
-
-
Repayments of short-term convertible debt
-
-
3,400
-
Repayments of loan payable
-
81
-
-
Proceeds from issuance of pre-funded warrants, net of direct costs
2,584
-
-
-
Proceeds from issuance of common stock, net of direct costs
2,862
706
6,590
0
Net cash provided by financing activities
5,324
952
3,190
0
Net decrease in cash and cash equivalents
2,033
-3,412
27
-3,978
Cash and cash equivalents, beginning of period
1,482
4,894
4,867
13,985
Cash and cash equivalents, end of period
3,515
1,482
4,894
4,867
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock, net of...
$2,862K
Proceeds from issuance of
pre-funded warrants, net of...
$2,584K
Proceeds from short-term
convertible debt
$327K
Net cash provided by
financing activities
$5,324K
(21.69%↑ Y/Y)
Canceled cashflow
$203K
Net decrease in cash
and cash...
$2,033K
(139.55%↑ Y/Y)
Canceled cashflow
$3,291K
Repayments of short-term
borrowing
$203K
Accounts payable and
accrued expenses
$971K
(250.31%↑ Y/Y)
Stock-based compensation
expense
$707K
(-44.77%↓ Y/Y)
Prepaid expenses
-$492K
(-144.40%↓ Y/Y)
Other current assets
-$403K
(-2138.89%↓ Y/Y)
Amortization of operating
lease right-of-use...
$95K
(-62.60%↓ Y/Y)
Depreciation expense
$66K
(-41.59%↓ Y/Y)
Net cash used in
operating activities
-$3,291K
(64.46%↑ Y/Y)
Canceled cashflow
$2,734K
Net loss
-$4,117K
Research and development
supplies and other...
$1,807K
Operating lease liability
-$69K
(72.40%↑ Y/Y)
Gain on termination
of operating lease
$32K
Buy us a coffee
FibroBiologics, Inc. (FBLG)
FibroBiologics, Inc. (FBLG)